Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04666129
- Locations
- 🇺🇸
Clinical Research Alliance, Inc., Westbury, New York, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Alliance Urology, Greensboro, North Carolina, United States
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 352
- Registration Number
- NCT04662580
- Locations
- 🇺🇸
The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Urology Cancer Center, XCancer Research Network, Omaha, Nebraska, United States
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-11-01
- Target Recruit Count
- 415
- Registration Number
- NCT04647526
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸Greater Dayton Cancer Center, Kettering, Ohio, United States
🇺🇸Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT04631601
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California at Irvine Medical Center, Orange, California, United States
🇺🇸University of California San Francisco Mission Bay Campus, San Francisco, California, United States
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04628988
- Locations
- 🇺🇸
Local Institution - 101, New York, New York, United States
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 19
- Registration Number
- NCT04556617
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1012
- Registration Number
- NCT04493853
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT04477512
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Abiraterone Acetate in Combination With Tildrakizumab
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 13
- Registration Number
- NCT04458311
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, UK, United Kingdom
🇬🇧Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom
🇬🇧The Royal Marsden Hospital Foundation Trust, Sutton, UK, United Kingdom
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 575
- Registration Number
- NCT04446117
- Locations
- 🇺🇸
Exelixis Clinical Site #6, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #18, Philadelphia, Pennsylvania, United States
🇵🇱Exelixis Clinical Site #243, Otwock, Mazowieckie, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.